Targeting the DNA damage response in cancer

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The DNA damage response (DDR) pathway is essential for maintaining genomic stability.
• Mutations in DDR proteins are common in human cancers, promoting genomic instability.
• DDR defects create vulnerabilities that can be exploited for cancer therapy.

Purpose of the Study:

• To review the current state of DDR inhibitors in cancer treatment.
• To highlight the therapeutic potential of targeting DDR pathways.
• To discuss the clinical trial results of specific DDR inhibitors.

Main Methods:

• Review of scientific literature on DDR inhibitors.
• Analysis of clinical trial data for DDR inhibitors.
• Discussion of synthetic lethality approaches in cancer therapy.

Main Results:

• DDR inhibitors show antitumor activity in human cancers.
• Inhibition of DDR can sensitize cancer cells to chemotherapy and radiotherapy.
• Synthetic lethality strategies are expanding the use of DDR inhibitors.

Conclusions:

• Targeting the DDR pathway is a promising therapeutic strategy for cancer.
• DDR inhibitors are effective in monotherapy and combination treatments.
• Ongoing research continues to broaden the application of DDR inhibitors.